IT 174
Latest Information Update: 21 May 2001
Price :
$50 *
At a glance
- Originator Nonindustrial source
- Class Lactones
- Mechanism of Action Macrophage inhibitors; Monocyte inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Allotransplant rejection
Most Recent Events
- 21 May 2001 No-Development-Reported for Allotransplant rejection in France (Unknown route)
- 21 May 2001 No-Development-Reported for Allotransplant rejection in Japan (Unknown route)
- 21 May 2001 No-Development-Reported for Allotransplant rejection in USA (Unknown route)